Technologies, Platforms and Companies

Which technologies will have the most success, and which companies are respondents most excited about for each modality?

Which enabling technologies or platforms do you believe will have the most success for development of different therapeutics? (Click to expand any of the charts)

In general, machine learning/Artificial Intelligence and novel screening are the technologies respondents hold most hope for the development of the different therapeutics. As these charts show, unsurprisingly, different technologies are seen as more promising for some modalities than others.

Which companies working on different modalities are you most excited about?

Protein therapeutics

1) Roche (21%)
=2) Amgen (12%)
=2) Genentech (12%)
=4) Merck (8%)
=4) Regeneron (8%)

mAbs

1) Roche (18%)
=2) Genentech (16%)
=2) Regeneron (16%)
4) Amgen (8%)
5) Chugai (6%)

Bispecifics

1) Roche (19%)
=2) Chugai (14%)
=2) Genentech (14%)
=4) TeneoBio, Genmab, Regeneron, Xencor (all 10%)

ADCs

1) Seattle Genetics (38%)
2) Daiichi Sankyo (23%)

Immuno-oncology: Checkpoints

1) Roche (26%)
2) Merck (16%)

Roche is consistently the company respondents are most excited about in terms of the development of different antibody therapeutics, topping the responses for mAbs, protein therapeutics, bispecifics and immuno-oncology checkpoints. Regeneron and Genentech both also rated highly.